

## Buparvaquone Formulation

Version 3.1      Revision Date: 30.09.2023      SDS Number: 2091173-00014      Date of last issue: 04.04.2023  
 Date of first issue: 17.10.2017

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Buparvaquone Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-stance/Mixture : Veterinary product

Recommended restrictions on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : MSD  
 20 Spartan Road  
 1619 Spartan, South Africa

Telephone : +27119239300

E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

#### 1.4 Emergency telephone number

+1-908-423-6000

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

Skin irritation, Category 2	H315: Causes skin irritation.
Eye irritation, Category 2	H319: Causes serious eye irritation.
Reproductive toxicity, Category 1B	H360D: May damage the unborn child.
Specific target organ toxicity - single exposure, Category 3	H335: May cause respiratory irritation.
Short-term (acute) aquatic hazard, Category 1	H400: Very toxic to aquatic life.
Long-term (chronic) aquatic hazard, Category 1	H410: Very toxic to aquatic life with long lasting effects.

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Danger

## Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	2091173-00014	Date of first issue: 17.10.2017

Hazard statements : H315 Causes skin irritation.  
 H319 Causes serious eye irritation.  
 H335 May cause respiratory irritation.  
 H360D May damage the unborn child.  
 H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**  
 P201 Obtain special instructions before use.  
 P264 Wash skin thoroughly after handling.  
 P273 Avoid release to the environment.  
 P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**  
 P308 + P313 IF exposed or concerned: Get medical advice/ attention.  
 P391 Collect spillage.

Hazardous components which must be listed on the label:  
 N-Methyl-2-pyrrolidone

**Additional Labelling**

Restricted to professional users.

**2.3 Other hazards**

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

**SECTION 3: Composition/information on ingredients****3.2 Mixtures****Components**

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
N-Methyl-2-pyrrolidone	872-50-4 212-828-1 606-021-00-7	Skin Irrit. 2; H315 Eye Irrit. 2; H319 Repr. 1B; H360D STOT SE 3; H335	>= 50 - < 70
Buparvaquone	88426-33-9	Eye Irrit. 2; H319 Aquatic Acute 1; H400 Aquatic Chronic 1; H410  M-Factor (Acute aquatic toxicity): 10 M-Factor (Chronic aquatic toxicity): 10	>= 2,5 - < 10

## Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	2091173-00014	Date of first issue: 17.10.2017

---

For explanation of abbreviations see section 16.

---

### SECTION 4: First aid measures

#### 4.1 Description of first aid measures

- |                            |   |  |
|----------------------------|---|--|
| General advice             | : | In the case of accident or if you feel unwell, seek medical advice immediately.<br>When symptoms persist or in all cases of doubt seek medical advice.   |
| Protection of first-aiders | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).  |
| If inhaled                 | : | If inhaled, remove to fresh air.<br>Get medical attention.   |
| In case of skin contact    | : | In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.<br>Get medical attention.<br>Wash clothing before reuse.<br>Thoroughly clean shoes before reuse. |
| In case of eye contact     | : | In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.<br>If easy to do, remove contact lens, if worn.<br>Get medical attention.   |
| If swallowed               | : | If swallowed, DO NOT induce vomiting.<br>Get medical attention.<br>Rinse mouth thoroughly with water.  |

#### 4.2 Most important symptoms and effects, both acute and delayed

- |       |   |  |
|-------|---|--|
| Risks | : | Causes skin irritation.<br>Causes serious eye irritation.<br>May cause respiratory irritation.<br>May damage the unborn child. |
|-------|---|--|

#### 4.3 Indication of any immediate medical attention and special treatment needed

- |           |   |   |
|-----------|---|---|
| Treatment | : | Treat symptomatically and supportively. |
|-----------|---|---|

---

### SECTION 5: Firefighting measures

#### 5.1 Extinguishing media

- |                              |   |  |
|------------------------------|---|--|
| Suitable extinguishing media | : | Water spray<br>Alcohol-resistant foam<br>Carbon dioxide (CO <sub>2</sub> )<br>Dry chemical |
|------------------------------|---|--|

## Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	2091173-00014	Date of first issue: 17.10.2017

---

Unsuitable extinguishing media : None known.

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Nitrogen oxides (NO<sub>x</sub>)

### 5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

## SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

## Buparvaquone Formulation

Version      Revision Date:      SDS Number:      Date of last issue: 04.04.2023  
3.1            30.09.2023            2091173-00014      Date of first issue: 17.10.2017

---

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

---

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.  
Avoid breathing mist or vapours.  
Do not swallow.  
Do not get in eyes.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers.  
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### 7.2 Conditions for safe storage, including any incompatibilities

- Requirements for storage areas and containers : Keep in properly labelled containers. Store locked up. Keep tightly closed. Keep in a cool, well-ventilated place. Store in accordance with the particular national regulations.
- Advice on common storage : Do not store with the following product types:  
Strong oxidizing agents  
Self-reactive substances and mixtures  
Organic peroxides  
Explosives  
Gases

### 7.3 Specific end use(s)

- Specific use(s) : No data available

## Buparvaquone Formulation

Version 3.1      Revision Date: 30.09.2023      SDS Number: 2091173-00014      Date of last issue: 04.04.2023  
 Date of first issue: 17.10.2017

**SECTION 8: Exposure controls/personal protection****8.1 Control parameters****Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
N-Methyl-2-pyrrolidone	872-50-4	TWA	10 ppm 40 mg/m <sup>3</sup>	2009/161/EU
		STEL	20 ppm 80 mg/m <sup>3</sup>	2009/161/EU
		TWA	10 ppm 40 mg/m <sup>3</sup>	2004/37/EC
		STEL	20 ppm 80 mg/m <sup>3</sup>	2004/37/EC
Buparvaquone	88426-33-9	TWA	40 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	400 µg/100 cm <sup>2</sup>	Internal

**Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:**

Substance name	End Use	Exposure routes	Potential health effects	Value
N-Methyl-2-pyrrolidone	Workers	Inhalation	Long-term systemic effects	14,4 mg/m <sup>3</sup>
			Long-term local effects	40 mg/m <sup>3</sup>
		Skin contact	Long-term systemic effects	4,8 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	3,6 mg/m <sup>3</sup>
			Long-term local effects	4,5 mg/m <sup>3</sup>
		Skin contact	Long-term systemic effects	2,4 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	0,85 mg/kg bw/day

**Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:**

Substance name	Environmental Compartment	Value	
N-Methyl-2-pyrrolidone	Fresh water	0,25 mg/l	
	Freshwater - intermittent	5 mg/l	
	Marine water	0,025 mg/l	
	Sewage treatment plant	10 mg/l	
	Fresh water sediment		1,09 mg/kg dry weight (d.w.)
		Marine sediment	1,09 mg/kg dry weight (d.w.)
	Soil	0,07 mg/kg dry weight (d.w.)	

## Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	2091173-00014	Date of first issue: 17.10.2017

---

### 8.2 Exposure controls

#### Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

#### Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Combined particulates and organic vapour type (A-P)

---

## SECTION 9: Physical and chemical properties

### 9.1 Information on basic physical and chemical properties

Appearance	:	liquid
Colour	:	clear, red
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable

**Buparvaquone Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	2091173-00014	Date of first issue: 17.10.2017

---

Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	1 (20 °C)
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

**9.2 Other information**

Flammability (liquids)	:	No data available
Particle size	:	Not applicable

---

**SECTION 10: Stability and reactivity****10.1 Reactivity**

Not classified as a reactivity hazard.

**10.2 Chemical stability**

Stable under normal conditions.

**10.3 Possibility of hazardous reactions**

Hazardous reactions	:	Can react with strong oxidizing agents.
---------------------	---	---

**10.4 Conditions to avoid**

Conditions to avoid	:	None known.
---------------------	---	-------------

**10.5 Incompatible materials**

Materials to avoid	:	Oxidizing agents
--------------------	---	------------------



## Buparvaquone Formulation

Version 3.1      Revision Date: 30.09.2023      SDS Number: 2091173-00014      Date of last issue: 04.04.2023  
Date of first issue: 17.10.2017

---

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

---

## SECTION 11: Toxicological information

### 11.1 Information on toxicological effects

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Components:

##### **N-Methyl-2-pyrrolidone:**

Acute oral toxicity : LD50 (Rat): 4.150 mg/kg  
Acute inhalation toxicity : LC50 (Rat): > 5,1 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Method: OECD Test Guideline 403  
Acute dermal toxicity : LD50 (Rat): > 5.000 mg/kg

##### **Buparvaquone:**

Acute oral toxicity : LD50 (Rat): > 8.000 mg/kg  
LD50 (Mouse): > 50 mg/kg  
Remarks: No mortality observed at this dose.  
Acute toxicity (other routes of administration) : LD50: 2,5 mg/kg  
Application Route: Intravenous

#### **Skin corrosion/irritation**

Causes skin irritation.

#### Components:

##### **N-Methyl-2-pyrrolidone:**

Result : Skin irritation

##### **Buparvaquone:**

Species : Mouse  
Result : Mild skin irritation

#### **Serious eye damage/eye irritation**

Causes serious eye irritation.

#### Components:

##### **N-Methyl-2-pyrrolidone:**

## Buparvaquone Formulation

Version 3.1      Revision Date: 30.09.2023      SDS Number: 2091173-00014      Date of last issue: 04.04.2023  
Date of first issue: 17.10.2017

---

Species : Rabbit  
Result : Irritation to eyes, reversing within 21 days

**Buparvaquone:**

Result : Mild eye irritation

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Components:****N-Methyl-2-pyrrolidone:**

Test Type : Local lymph node assay (LLNA)  
Exposure routes : Skin contact  
Species : Mouse  
Method : OECD Test Guideline 429  
Result : negative  
Remarks : Based on data from similar materials

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****N-Methyl-2-pyrrolidone:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Method: OECD Test Guideline 471  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Method: OECD Test Guideline 476  
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Method: OECD Test Guideline 474  
Result: negative

Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)  
Species: Hamster  
Application Route: Ingestion  
Method: OECD Test Guideline 475

## Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	2091173-00014	Date of first issue: 17.10.2017

---

Result: negative

### Carcinogenicity

Not classified based on available information.

### Components:

#### **N-Methyl-2-pyrrolidone:**

Species : Rat  
 Application Route : Ingestion  
 Exposure time : 2 Years  
 Result : negative

Species : Rat  
 Application Route : inhalation (vapour)  
 Exposure time : 2 Years  
 Result : negative

### Reproductive toxicity

May damage the unborn child.

### Components:

#### **N-Methyl-2-pyrrolidone:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
 Species: Rat  
 Application Route: Ingestion  
 Method: OECD Test Guideline 416  
 Result: negative

Effects on foetal development : Test Type: Embryo-foetal development  
 Species: Rat  
 Application Route: Ingestion  
 Method: OECD Test Guideline 414  
 Result: positive

Test Type: Fertility/early embryonic development  
 Species: Rat  
 Application Route: inhalation (vapour)  
 Result: positive

Test Type: Embryo-foetal development  
 Species: Rabbit  
 Application Route: Ingestion  
 Result: positive

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

### **STOT - single exposure**

May cause respiratory irritation.

**Buparvaquone Formulation**

Version 3.1      Revision Date: 30.09.2023      SDS Number: 2091173-00014      Date of last issue: 04.04.2023  
Date of first issue: 17.10.2017

---

**Components:****N-Methyl-2-pyrrolidone:**

Assessment : May cause respiratory irritation.

**STOT - repeated exposure**

Not classified based on available information.

**Repeated dose toxicity****Components:****N-Methyl-2-pyrrolidone:**

Species : Rat, male  
NOAEL : 169 mg/kg  
LOAEL : 433 mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days  
Method : OECD Test Guideline 408

Species : Rat  
NOAEL : 0,5 mg/l  
LOAEL : 1 mg/l  
Application Route : inhalation (dust/mist/fume)  
Exposure time : 96 Days  
Method : OECD Test Guideline 413

Species : Rabbit  
NOAEL : 826 mg/kg  
LOAEL : 1.653 mg/kg  
Application Route : Skin contact  
Exposure time : 20 Days

**Buparvaquone:**

Species : Cat  
NOAEL : 10 mg/kg  
Application Route : Intramuscular  
Exposure time : 5 d  
Remarks : No significant adverse effects were reported

NOAEL : 5 mg/kg  
Application Route : Intravenous  
Exposure time : 4 d  
Remarks : No significant adverse effects were reported

Species : Mouse  
NOAEL : 50 mg/kg  
Application Route : Oral  
Exposure time : 6 d  
Remarks : No significant adverse effects were reported

**Aspiration toxicity**

Not classified based on available information.

## Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	2091173-00014	Date of first issue: 17.10.2017

---

### Experience with human exposure

#### Components:

##### **N-Methyl-2-pyrrolidone:**

Skin contact : Symptoms: Skin irritation

---

## SECTION 12: Ecological information

### 12.1 Toxicity

#### Components:

##### **N-Methyl-2-pyrrolidone:**

Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): > 500 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 1.000 mg/l Exposure time: 24 h Method: DIN 38412
Toxicity to algae/aquatic plants	:	ErC50 (Desmodesmus subspicatus (green algae)): 600,5 mg/l Exposure time: 72 h  EC10 (Desmodesmus subspicatus (green algae)): 92,6 mg/l Exposure time: 72 h
Toxicity to microorganisms	:	EC50 : > 600 mg/l Exposure time: 30 min Method: ISO 8192
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC: 12,5 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

##### **Buparvaquone:**

Toxicity to fish	:	LC50 (Brachydanio rerio (zebrafish)): 0,484 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 0,013 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
M-Factor (Acute aquatic toxicity)	:	10
M-Factor (Chronic aquatic toxicity)	:	10

## Buparvaquone Formulation

Version 3.1      Revision Date: 30.09.2023      SDS Number: 2091173-00014      Date of last issue: 04.04.2023  
Date of first issue: 17.10.2017

---

### 12.2 Persistence and degradability

#### Components:

##### **N-Methyl-2-pyrrolidone:**

Biodegradability : Result: Readily biodegradable.  
Biodegradation: 73 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301C

### 12.3 Bioaccumulative potential

#### Components:

##### **N-Methyl-2-pyrrolidone:**

Partition coefficient: n-octanol/water : log Pow: -0,46  
Method: OECD Test Guideline 107

##### **Buparvaquone:**

Partition coefficient: n-octanol/water : log Pow: 6,5

### 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Other adverse effects

#### Product:

Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

---

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.

## Buparvaquone Formulation

Version 3.1      Revision Date: 30.09.2023      SDS Number: 2091173-00014      Date of last issue: 04.04.2023  
 Date of first issue: 17.10.2017

If not otherwise specified: Dispose of as unused product.

### SECTION 14: Transport information

#### 14.1 UN number

**ADN** : UN 3082  
**ADR** : UN 3082  
**RID** : UN 3082  
**IMDG** : UN 3082  
**IATA** : UN 3082

#### 14.2 UN proper shipping name

**ADN** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(Buparvaquone)  
**ADR** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(Buparvaquone)  
**RID** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(Buparvaquone)  
**IMDG** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(Buparvaquone)  
**IATA** : Environmentally hazardous substance, liquid, n.o.s.  
(Buparvaquone)

#### 14.3 Transport hazard class(es)

	Class	Subsidiary risks
<b>ADN</b>	: 9	
<b>ADR</b>	: 9	
<b>RID</b>	: 9	
<b>IMDG</b>	: 9	
<b>IATA</b>	: 9	

#### 14.4 Packing group

**ADN**  
 Packing group : III  
 Classification Code : M6  
 Hazard Identification Number : 90  
 Labels : 9

**ADR**  
 Packing group : III  
 Classification Code : M6  
 Hazard Identification Number : 90  
 Labels : 9

## Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	2091173-00014	Date of first issue: 17.10.2017

---

Tunnel restriction code : (-)

### RID

Packing group : III  
 Classification Code : M6  
 Hazard Identification Number : 90  
 Labels : 9

### IMDG

Packing group : III  
 Labels : 9  
 EmS Code : F-A, S-F

### IATA (Cargo)

Packing instruction (cargo aircraft) : 964  
 Packing instruction (LQ) : Y964  
 Packing group : III  
 Labels : Miscellaneous

### IATA (Passenger)

Packing instruction (passenger aircraft) : 964  
 Packing instruction (LQ) : Y964  
 Packing group : III  
 Labels : Miscellaneous

## 14.5 Environmental hazards

### ADN

Environmentally hazardous : yes

### ADR

Environmentally hazardous : yes

### RID

Environmentally hazardous : yes

### IMDG

Marine pollutant : yes

### IATA (Passenger)

Environmentally hazardous : yes

### IATA (Cargo)

Environmentally hazardous : yes

## 14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

## 14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.



## Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	2091173-00014	Date of first issue: 17.10.2017

### SECTION 15: Regulatory information

#### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

#### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

### SECTION 16: Other information

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
-------------------	---	--

#### Full text of H-Statements

H315	:	Causes skin irritation.
H319	:	Causes serious eye irritation.
H335	:	May cause respiratory irritation.
H360D	:	May damage the unborn child.
H400	:	Very toxic to aquatic life.
H410	:	Very toxic to aquatic life with long lasting effects.

#### Full text of other abbreviations

Aquatic Acute	:	Short-term (acute) aquatic hazard
Aquatic Chronic	:	Long-term (chronic) aquatic hazard
Eye Irrit.	:	Eye irritation
Repr.	:	Reproductive toxicity
Skin Irrit.	:	Skin irritation
STOT SE	:	Specific target organ toxicity - single exposure
2004/37/EC	:	Europe. Directive 2004/37/EC on the protection of workers from the risks related to exposure to carcinogens or mutagens at work
2009/161/EU	:	Europe. COMMISSION DIRECTIVE 2009/161/EU establishing a third list of indicative occupational exposure limit values in implementation of Council Directive 98/24/EC and amending Commission Directive 2000/39/EC
2004/37/EC / STEL	:	Short term exposure limit
2004/37/EC / TWA	:	Long term exposure limit
2009/161/EU / TWA	:	Limit Value - eight hours
2009/161/EU / STEL	:	Short term exposure limit

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regula-

## Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	2091173-00014	Date of first issue: 17.10.2017

tion (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

**Classification of the mixture:**

Skin Irrit. 2	H315
Eye Irrit. 2	H319
Repr. 1B	H360D
STOT SE 3	H335
Aquatic Acute 1	H400
Aquatic Chronic 1	H410

**Classification procedure:**

Calculation method
Calculation method
Calculation method
Calculation method
Calculation method
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

# SAFETY DATA SHEET



## Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	2091173-00014	Date of first issue: 17.10.2017

---

ZA / EN